KalVista Pharmaceuticals Inc. Watch

from 8-K 17 pages Amended and Restated Executive Employment Agreement

from 8-K 17 pages Amended and Restated Executive Employment Agreement

from 8-K 17 pages Executive Employment Agreement

from 10-Q 19 pages March 6, 2024 via E-Mail T. Andrew Crockett [***] Re: Terms of Separation Dear Andrew: This Letter Confirms the Agreement (This “Agreement”) Between You and KalVista Pharmaceuticals, Inc. (The “Company”) Concerning the Terms of Your Separation and Offers You the Separation Compensation We Discussed in Exchange for a General Release of Claims and Covenant Not to Sue. 1. Separation Date: March 6, 2024 Is Your Last Day of Employment With the Company (The “Separation Date”). 2. Resignation From Officer Positions and Board Membership: Effective as of the Separation Date, You Hereby Resign From All Officer Positions and All Positions on the Company’s Board of Directors (The “Board”) Without the Need of Acceptance or Any Further Action by the Company. 3

from 10-Q 61 pages Lease Agreement

from 10-K 20 pages Amended and Restated Executive Employment Agreement

from 8-K 16 pages Amended and Restated Executive Employment Agreement

from 8-K 11 pages Form of Subscription Agreement

from 10-K 70 pages 1.purpose. the Purpose of This Plan Is to Provide Incentives to Attract and Motivate Eligible Employees Whose Potential Contributions Are Important to the Success of the Company, and Any Parents, Subsidiaries and Affiliates That Exist Now or in the Future, by Offering Them an Opportunity to Participate in the Company’s Future Performance Through the Grant of Awards. Capitalized Terms Not Defined Elsewhere in the Text Are Defined in Section 22. 2. Shares Subject to the Plan

from 10-K 15 pages Executive Employment Agreement

from 10-Q 19 pages First Amendment of Lease

from 10-K 5 pages Description of Registrant’s Securities

from 10-K 6 pages Deed of Variation of Contract (1)kalvista Pharmaceuticals Limited (2)dr Christopher Yea

from 10-K 15 pages Executive Employment Agreement

from 10-K 15 pages Amended and Restated Executive Employment Agreement

from 10-K 15 pages Amended and Restated Executive Employment Agreement

from 10-K 15 pages Amended and Restated Executive Employment Agreement

from 10-K 15 pages Amended and Restated Executive Employment Agreement

from 10-Q 1 page March 11, 2019 Sincerely, KalVista Pharmaceuticals, Inc. By: /S/ Benjamin L. Palleiko Name: Benjamin L. Palleiko Title:chief Financial Officer

from 10-Q 7 pages Deed of Variation of Contract (1)kalvista Pharmaceuticals Limited (2)dr Christopher Yea